This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 337 studies, archived under the term: "neuropsychological tests"

Click here to filter this large number of results.

Economic evaluation of an integrated diagnostic approach for psychogeriatric patients: results of a randomized controlled trial

Context: Because of the increasing number of elderly people with dementia, the costs of dementia and dementia care are expected to grow rapidly in the coming decades. Cost-effectiveness results are relevant for decision making about new strategies in dementia care.; Objective: To evaluate the cost-effectiveness of an integrated multidisciplinary diagnostic facility for diagnosing dementia in […]

Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer’s disease

Background: Therapeutic endpoints based on reduced clinical worsening represent clinically relevant and realistic goals for patients suffering from progressive neurodegenerative disorders such as Alzheimer’s disease (AD).; Methods: Data from 906 patients (388 receiving placebo; 518 receiving donepezil) with mild-to-moderate AD [Mini-Mental State Examination (MMSE) score 10-27] were pooled from 3 randomized, double-blind placebo-controlled studies. Clinical […]

Effects of insulin and octreotide on memory and growth hormone in Alzheimer’s disease

Both insulin alone and the somatostatin analogue octreotide alone facilitate memory in patients with Alzheimer’s disease (AD). Since octreotide inhibits endogenous insulin secretion, the cognitive effects of insulin and octreotide may not be independent. This study tested the individual and interactive effects of insulin and octreotide on memory and plasma growth hormone (GH) levels in […]

Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression

Objectives: Agitation/aggression in Alzheimer disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine (NE) release may contribute to the pathophysiology of agitation/aggression in AD. Prazosin, a nonsedating generic medication used for hypertension and benign prostatic hypertrophy, antagonizes NE effects at brain postsynaptic alpha-1 […]

Responders to ChEI treatment of Alzheimer’s disease show restitution of normal regional cortical activation

Clinical trials of cholinesterase inhibitor (ChEI) drugs, although generally reporting only minimal improvements in patients with Alzheimer’s disease (AD), indicate that a subgroup of patients may respond substantially to treatment. This study aimed to assess the clinically variable ChEI treatment effects in a group of patients with mild AD using a semantic association and an […]

Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial

Context: The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging. However, evidence from adequately powered clinical trials is lacking regarding its effect on long-term cognitive functioning.; Objective: To determine whether G. biloba slows the rates of global or domain-specific cognitive decline in older adults.; Design, Setting, and […]

Long-term effects of rivastigmine capsules in patients with traumatic brain injury

Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study.; Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (< or […]

Orally disintegrating donepezil: are the main caregivers of patients with Alzheimer’s disease more satisfied with this formulation of donepezil than with the traditional one?

Aim: To know whether caregivers of Alzheimer’s disease (AD) patients on donepezil treatment are more satisfied with the orally disintegrating tablet (ODT) formulation than with the film-coated tablets.; Patients and Methods: Multicenter, cross-sectional study of patients with probably AD by DSM-IV or NINCDS-ADRDA criteria, on monotherapy with donepezil, ODT or film-coated tablets. Satisfaction with treatment […]

Addenbrooke’s Cognitive Examination validation in Parkinson’s disease

Background: There is a clear need for brief, sensitive and specific cognitive screening instruments in Parkinson’s disease (PD).; Objectives: To study Addenbrooke’s Cognitive Examination (ACE) validity for cognitive assessment of PD patient’s using the Mattis Dementia Rating Scale (MDRS) as reference method. A specific scale for cognitive evaluation in PD, in this instance the Scales […]

Methodological improvements in quantifying cognitive change in clinical trials: an example with single-dose administration of donepezil

Objectives: Change in cognitive function in response to a pharmacologic challenge can be observed with greater sensitivity by employing cognitive tests with optimal psychometric properties and a statistical approach that more accurately accounts for individual variability in performance. To demonstrate this approach we examined the cognitive effects of a single acute dose administration of an […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: